

NOVAVAX INC  
Form SC 13D/A  
April 09, 2001

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D  
Under the Securities Exchange Act of 1934

Amendment No.: 2

Name of Issuer: Novavax, Inc.

Title of Class of Securities: Common Stock

CUSIP Number: 670002104

(Name, Address and Telephone Number of Person  
Authorized To Receive Notices and Communications)

Mr. Peter Amato, c/o Anaconda Capital Management, LLC,  
730 Fifth Avenue, 15th Floor, New York, NY 10019, (212) 698-9600

(Date of Event which Requires Filing of this Statement)

April 5, 2001

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ☐ ].

Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: NOVAVAX INC - Form SC 13D/A

CUSIP No. 670002104

1. Name of Reporting Person  
S.S. or I.R.S. Identification No. of Above Person

Anaconda Opportunity Fund, L.P.

2. Check the Appropriate Box if a Member of a Group

a.  
b. ☒ x

3. SEC Use Only

4. Source of Funds

WC

5. Check if Disclosure of Legal Proceedings is Required Pursuant  
to Items 2(d) or 2(e)

6. Citizenship or Place of Organization

New York

Number of Shares Beneficially Owned by Each Reporting Person  
With:

7. Sole Voting Power:

8. Shared Voting Power:

2,080,962

9. Sole Dispositive Power:

10. Shared Dispositive Power:

2,080,962

11. Aggregate Amount Beneficially Owned by Each Reporting Person

2,080,962

12. Check Box if the Aggregate Amount in Row (11) Excludes  
Certain Shares

2

13. Percent of Class Represented by Amount in Row (11)

Edgar Filing: NOVAVAX INC - Form SC 13D/A

9.35%

14. Type of Reporting Person

PN

3

CUSIP No. 670002104

1. Name of Reporting Person  
S.S. or I.R.S. Identification No. of Above Person

## Edgar Filing: NOVAVAX INC - Form SC 13D/A

Anaconda Capital, L.P.

2. Check the Appropriate Box if a Member of a Group

- a.
- b. ☒

3. SEC Use Only

4. Source of Funds

AF

5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

6. Citizenship or Place of Organization

Delaware

Number of Shares Beneficially Owned by Each Reporting Person With:

7. Sole Voting Power:

8. Shared Voting Power:

2,080,962

9. Sole Dispositive Power:

10. Shared Dispositive Power:

2,080,962

11. Aggregate Amount Beneficially Owned by Each Reporting Person

2,080,962

12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares

4

13. Percent of Class Represented by Amount in Row (11)

9.35%

14. Type of Reporting Person

PN

5

CUSIP No. 670002104

1. Name of Reporting Person  
S.S. or I.R.S. Identification No. of Above Person

Mitchell J. Kelly

2. Check the Appropriate Box if a Member of a Group

- a.
- b. ☒ x

Edgar Filing: NOVAVAX INC - Form SC 13D/A

3. SEC Use Only

4. Source of Funds

AF

5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

6. Citizenship or Place of Organization

U.S.A.

Number of Shares Beneficially Owned by Each Reporting Person  
With:

7. Sole Voting Power:

99,139

8. Shared Voting Power:

2,080,962

9. Sole Dispositive Power:

99,139

10. Shared Dispositive Power:

2,080,962

11. Aggregate Amount Beneficially Owned by Each Reporting Person

2,180,101

12. Check Box if the Aggregate Amount in Row (11) Excludes  
Certain Shares

6

13. Percent of Class Represented by Amount in Row (11)

9.53%

14. Type of Reporting Person

IN

7

Item 1. SECURITY AND ISSUER

No change.

Item 2. IDENTITY AND BACKGROUND

No change.

Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

As of the date hereof, each of Anaconda and the Partnership beneficially owns 2,022,770 shares of Common Stock and 58,192 Warrants and each convertible into 1 share of Common Stock. Mr. Kelly is deemed to beneficially own 2,022,770 shares of Common Stock and 58,192 Warrants by virtue of having investment discretion over Anaconda and the Partnership. Mr. Kelly

## Edgar Filing: NOVAVAX INC - Form SC 13D/A

also beneficially owns 80,000 options to purchase Common Stock and 19,139 shares of Common Stock, which were granted to Mr. Kelly in connection with his role as a Board Member and Chief Executive Officer of the Company. Of the 2,022,770 shares of Common Stock, 852,777 shares were acquired through the exercise of warrants for common stock, and 220,000 shares were acquired through a private placement at an aggregate cost of \$550,000. The funds for the purchase of the Common Stock and Warrants came from the Partnership's working capital.

### Item 4. PURPOSE OF TRANSACTIONS.

No change.

### Item 5. INTEREST IN SECURITIES OF ISSUER.

As of the date hereof, each of Anaconda and the Partnership is the beneficial owner of 2,022,770 shares of Common Stock and 58,192 Warrants, each Warrant convertible into 1 share of Common Stock. Mr. Kelly is deemed to beneficially own 2,022,770 shares of Common Stock and 58,192 Warrants by virtue of having investment discretion over Anaconda and the Partnership. Mr. Kelly also beneficially owns 80,000 options, each option to purchase 1 share of Common Stock and 19,139 shares of Common Stock, which were granted to Mr. Kelly in connection with his role as Board Member and Chief Executive Officer of the Company. Based on information provided from the Company in its 10-K for the fiscal year ending December 31, 2000, 22,247,533 shares of Common Stock were outstanding as of March 16, 2001. Therefore, each of Anaconda and the Partnership is deemed to beneficially own 9.35% of the outstanding

8

shares of Common Stock and Mr. Kelly is deemed to beneficially own 9.53% of the outstanding shares of Common Stock assuming the conversion of 58,192 Warrants and the 80,000 options. The Reporting Persons share the power to vote, direct the vote, dispose of or direct the disposition of all the shares of Common Stock that they are currently deemed to beneficially own.

### Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

No change.

### Item 7. MATERIAL TO BE FILED AS EXHIBITS.

A description of the transactions in the shares of Common Stock that were effected by the Reporting Persons during the past 60 days is filed herewith as Exhibit A.



Edgar Filing: NOVAVAX INC - Form SC 13D/A

Signature

The undersigned, after reasonable inquiry and to the best of its knowledge and belief, certifies that the information set forth in this statement is true, complete and correct.

April 6, 2001

Anaconda Opportunity Fund, L.P.  
By: Anaconda Capital, L.P.  
General Partner

By: /s/ Mitchell J. Kelly

---

Mitchell J. Kelly  
Managing General Partner

9

Anaconda Capital, L.P.

By: /s/ Mitchell J. Kelly

---

Mitchell J. Kelly  
Managing General Partner

Mitchell J. Kelly

/s/ Mitchell J. Kelly

---

01474003.AC6

Exhibit A

SCHEDULE OF TRANSACTIONS

Date	Shares Purchased	Price per Share (Not Including Commission)
3/26/01	10,000	7.808
3/27/01	3,000	7.959
3/28/01	2,300	7.670
3/29/01	7,500	7.363
4/05/01	250,000	6.350

01474003.AC6